The novel desmopressin analogue [V4Q5]dDAVP inhibits angiogenesis, tumour growth and metastases in vasopressin type 2 receptor-expressing breast cancer models

被引:27
作者
Garona, Juan [1 ]
Pifano, Marina [1 ]
Orlando, Ulises D. [2 ]
Pastrian, Maria B. [3 ]
Iannucci, Nancy B. [3 ]
Ortega, Hugo H. [4 ]
Podesta, Ernesto J. [2 ]
Gomez, Daniel E. [1 ]
Ripoll, Giselle V. [1 ]
Alonso, Daniel F. [1 ]
机构
[1] Natl Univ Quilmes, Mol Oncol Lab, Bernal, Argentina
[2] Univ Buenos Aires, Sch Med, Dept Human Biochem, Biomed Res Inst INBIOMED, Buenos Aires, DF, Argentina
[3] Univ Buenos Aires, Sch Pharm & Biochem, Buenos Aires, DF, Argentina
[4] Natl Univ Litoral, Inst Vet Sci ICIVET CONICET, Esperanza, Santa Fe, Argentina
关键词
desmopressin analogue; V(4)Q(5)]dDAVP; breast carcinoma; vasopressin type 2 receptor; metastases; tumour vascularisation; VON-WILLEBRAND-FACTOR; MAMMARY-CARCINOMA; CELL-MIGRATION; PERIOPERATIVE DESMOPRESSIN; TREATMENT STRATEGIES; ENDOTHELIAL-CELLS; PROTEIN-KINASE; RESEARCH TOOLS; CAMP; OXYTOCIN;
D O I
10.3892/ijo.2015.2952
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Desmopressin (dDAVP) is a safe haemostatic agent with previously reported antitumour activity. It acts as a selective agonist for the V2 vasopressin membrane receptor (V2r) present on tumour cells and microvasculature. The purpose of this study was to evaluate the novel peptide derivative [V(4)Q(5)]dDAVP in V2r-expressing preclinical mouse models of breast cancer. We assessed antitumour effects of [V(4)Q(5)]dDAVP using human MCF-7 and MDA-MB-231 breast carcinoma cells, as well as the highly metastatic mouse F3II cell line. Effect on in vitro cancer cell growth was evaluated by cell proliferation and clonogenic assays. Cell cycle distribution was analysed by flow cytometry. In order to study the effect of intravenously administered [V(4)Q(5)]dDAVP on tumour growth and angiogenesis, breast cancer xenografts were generated in athymic mice. F3II cells were injected into syngeneic mice to evaluate the effect of [V(4)Q(5)]dDAVP on spontaneous and experimental metastatic spread. In vitro cytostatic effects of [V(4)Q(5)]dDAVP against breast cancer cells were greater than those of dDAVP, and associated with V2r-activated signal transduction and partial cell cycle arrest. In MDA-MB-231 xenografts, [V(4)Q(5)]dDAVP (0.3 mu g/kg, thrice a week) reduced tumour growth and angiogenesis. Treatment of F3II mammary tumour-bearing immunocompetent mice resulted in complete inhibition of metastatic progression. [V(4)Q(5)]dDAVP also displayed greater antimetastatic efficacy than dDAVP on experimental lung colonisation by F3II cells. The novel analogue was well tolerated in preliminary acute toxicology studies, at doses >= 300-fold above that required for anti-angiogenic/antimetastatic effects. Our data establish the preclinical activity of [V(4)Q(5)]dDAVP in aggressive breast cancer, providing the rationale for further clinical trials.
引用
收藏
页码:2335 / 2345
页数:11
相关论文
共 54 条
  • [1] Alonso DF, 2011, CURR PHARM BIOTECHNO, V12, P1974
  • [2] Antimetastatic effect of desmopressin in a mouse mammary tumor model
    Alonso, DF
    Skilton, G
    Farías, EF
    Joffé, EBD
    Gomez, DE
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 1999, 57 (03) : 271 - 275
  • [3] Efficacy of IP6 + inositol in the treatment of breast cancer patients receiving chemotherapy: prospective, randomized, pilot clinical study
    Bacic, Ivan
    Druzijanic, Nikica
    Karlo, Robert
    Skific, Ivan
    Jagic, Stjepan
    [J]. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2010, 29
  • [4] Molecularly targeted therapies for metastatic triple-negative breast cancer
    Bayraktar, Soley
    Glueck, Stefan
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2013, 138 (01) : 21 - 35
  • [5] Preclinical Development of Novel Rac1-GEF Signaling Inhibitors using a Rational Design Approach in Highly Aggressive Breast Cancer Cell Lines
    Cardama, Georgina A.
    Comin, Maria J.
    Hornos, Leandro
    Gonzalez, Nazareno
    Defelipe, Lucas
    Turjanski, Adrian G.
    Alonso, Daniel F.
    Gomez, Daniel E.
    Lorenzano Menna, Pablo
    [J]. ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2014, 14 (06) : 840 - 851
  • [6] A chemical biology approach identifies a beta-2 adrenergic receptor agonist that causes human tumor regression by blocking the Raf-1/Mek-1/Erk1/2 pathway
    Carie, A. E.
    Sebti, S. M.
    [J]. ONCOGENE, 2007, 26 (26) : 3777 - 3788
  • [7] Integrating signals between cAMP and MAPK pathways in breast cancer
    Castoria, Gabriella
    Migliaccio, Antimo
    D'Amato, Loredana
    Di Stasio, Rosina
    Ciociola, Alessandra
    Lombardi, Maria
    Bilancio, Antonio
    Di Domenico, Marina
    de Falco, Antonietta
    Auricchio, Ferdinando
    [J]. FRONTIERS IN BIOSCIENCE-LANDMARK, 2008, 13 : 1318 - 1327
  • [8] Molecular modeling of the human vasopressin V2 receptor/agonist complex
    Czaplewski, C
    Kazmierkiewicz, R
    Ciarkowski, J
    [J]. JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN, 1998, 12 (03) : 275 - 287
  • [9] Molecular modelling of the vasopressin V2 receptor/antagonist interactions
    Czaplewski, C
    Kazmierkiewicz, R
    Ciarkowski, J
    [J]. ACTA BIOCHIMICA POLONICA, 1998, 45 (01) : 19 - 26
  • [10] Altered Agonist Sensitivity of a Mutant V2 Receptor Suggests a Novel Therapeutic Strategy for Nephrogenic Diabetes Insipidus
    Erdelyi, Laszlo Sandor
    Balla, Andras
    Patocs, Attila
    Toth, Miklos
    Varnai, Peter
    Hunyady, Laszlo
    [J]. MOLECULAR ENDOCRINOLOGY, 2014, 28 (05) : 634 - 643